To develop a neural spheroid Alzheimer’s disease (AD) drug screening platform, we used GABAergic neurons that were genetically engineered to carry the apolipoprotein e4/4 (APOE4) allele, a genotype known to increase the risk for AD24,25. This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.